随着有效的靶向药物的出现，近几年，对于无法接受强化化疗的急性髓系白血病（AML）患者的治疗管理发生了重大变化。虽然现在在接受强化化疗治疗的患者中常规进行可测残留病变（MRD）检测以提高预后和可能指导治疗决策，但其在低强度方案中的价值尚不清楚。随着这些方案的受欢迎程度增加且可能与更高的反应率有关，需要更好地定义MRD评估的角色以及用于此目的的适当时间点和测定方法。本报告概述了在接受低强度方案治疗的AML患者中进行MRD测试的路线图。来自欧洲白血病网（ELN）- DAVID AML MRD工作组的专家审查了所有可用数据，提出了未来临床试验和实际临床中MRD测试的框架。 Delphi投票用于优化共识。在治疗AML患者中使用低强度方案进行MRD评估的统一标准的建立对于临床相关和优化测试，最终改善这些患者的治疗结果至关重要。© 2023 Wiley Periodicals LLC.

With the availability of effective targeted agents, significant changes have occurred in the management of patients with acute myeloid leukemia (AML) over the past several years, particularly for those considered unfit for intensive chemotherapy. While testing for measurable residual disease (MRD) is now routinely performed in patients treated with intensive chemotherapy to refine prognosis and, possibly, inform treatment decision-making, its value in the context of lower-intensity regimens is unclear. As such regimens have gained in popularity and can be associated with higher response rates, the need to better define the role of MRD assessment and the appropriate time points and assays used for this purpose has increased. This report outlines a roadmap for MRD testing in patients with AML treated with lower-intensity regimens. Experts from the European LeukemiaNet (ELN)-DAVID AML MRD working group reviewed all available data to propose a framework for MRD testing in future trials and clinical practice. A Delphi poll served to optimize consensus. Establishment of uniform standards for MRD assessments in lower-intensity regimens used in treating patients with AML is clinically relevant and important for optimizing testing and, ultimately, improving treatment outcomes of these patients.© 2023 Wiley Periodicals LLC.